<DOC>
	<DOCNO>NCT01469182</DOCNO>
	<brief_summary>This study assess safety profile short ragweed ( Ambrosia artemisiifolia ) participant ragweed-induced rhinoconjunctivitis without asthma . The primary objective compare treatment-emergent adverse event ( AEs ) participant treat short ragweed allergy immunotherapy tablet ( AIT ) treat placebo .</brief_summary>
	<brief_title>A Study Ragweed ( Ambrosia Artemisiifolia ) Allergy Immunotherapy Tablet Adults With Ragweed Allergies ( P05751 )</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>Clinical history physiciandiagnosed ragweedinduced allergic rhinoconjunctivitis 2 year duration , without asthma Must positive skin prick test response Ambrosia artemisiifolia Must force expiratory volume 1 second ( FEV1 ) least 70 % predict value Clinical laboratory test , electrocardiogram ( ECG ) vital sign conduct Screening Visit must within normal limit clinically acceptable investigator/sponsor Females childbearing potential must agree use medically accept method contraception Unstable asthma experience occurrence clinical deterioration asthma result emergency treatment , hospitalization due asthma , treatment systemic corticosteroid previous 3 month Received immunosuppressive treatment within 3 month History anaphylaxis cardiorespiratory symptom . History chronic urticaria angioedema Current severe atopic dermatitis Female subject breastfeeding , pregnant , intend become pregnant Has receive maintenance dos immunotherapy ragweed extract â‰¥1 month within last 5 year History allergy , hypersensitivity intolerance ingredient investigational medicinal product ( IMPs ) ( except Ambrosia artemisiifolia ) , selfinjectable epinephrine Unable comply use selfinjectable epinephrine Participating clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Immunology</keyword>
</DOC>